# Advanced Glycation End-products, Exercise, and Sarcopenia

> **NIH NIH F30** · UNIVERSITY OF TEXAS MED BR GALVESTON · 2020 · $42,713

## Abstract

PROJECT SUMMARY / ABSTRACT
The age-related loss of muscle mass, strength, and function, known as sarcopenia, represents one of the most
common conditions in older adults. Of these conditions, sarcopenia is the only one for which no FDA-approved
treatment exists. To promote independence and prevent disability in our aging population, the identification of
drug targets for sarcopenia is crucial. Type 2 Diabetes Mellitus (T2DM) is an ideal model for this purpose
because sarcopenia is accelerated in older people who have T2DM. It may be possible to identify new drug
targets for the accelerated sarcopenia of T2DM by contrasting pathway dysregulation in healthy older controls
and in patients with T2DM. One promising potential target, upregulated by the hyperglycemic milieu of T2DM,
is non-enzymatic protein glycosylation (known as glycation) and the subsequent formation of advanced
glycation end-products (AGE). This detrimental process is known to contribute to multiple conditions, including
T2DM, Alzheimer’s disease, and low-grade inflammation. Increased AGE concentration has previously been
linked to decreased muscle strength and function in cross-sectional studies. Furthermore, blocking AGE
accumulation in animal models improves muscle mass. However, the role of AGE in sarcopenia in humans has
yet to be substantiated. We propose that AGE represents a potential mediator of accelerated sarcopenia in
humans with T2DM. However, more preliminary evidence of muscle AGE responsiveness to existing treatment
modalities – such as resistance exercise – is needed to design specific clinical trials. The proposed ancillary
study to parent R01 AG049611 will examine AGE in older subjects with T2DM and healthy controls before and
after 12 weeks of progressive resistance exercise training. We hypothesize that progressive resistance
exercise training will reduce AGE concentrations in plasma and muscle, and that these reductions will be
associated with improved sarcopenia outcomes – namely, muscle mass, strength, and function. We will also
test the hypothesis that progressive resistance exercise training can improve protein glycation and AGE
accumulation in T2DM older patients to levels not different from that of healthy older controls. By employing
clinical, proteomic, and biochemical methodologies, the present study will address this hypothesis through
three Specific Aims: 1) identify and quantify glycated protein targets in the skeletal muscle and plasma from
older adults with and without T2DM, 2) identify the effects of progressive resistance exercise training on AGE
concentration and downstream effectors of AGE, and 3) determine whether AGE concentration is associated
with baseline differences or intervention-induced changes in measures of muscle mass, strength, or function,
and estimate how much of the variation in these measures is explained by AGE concentration. Determining
the impact of progressive resistance exercise training on AGE accumulation will inform th...

## Key facts

- **NIH application ID:** 9984244
- **Project number:** 5F30AG058381-04
- **Recipient organization:** UNIVERSITY OF TEXAS MED BR GALVESTON
- **Principal Investigator:** Amanda Randolph
- **Activity code:** F30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $42,713
- **Award type:** 5
- **Project period:** 2017-09-15 → 2022-06-15

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9984244

## Citation

> US National Institutes of Health, RePORTER application 9984244, Advanced Glycation End-products, Exercise, and Sarcopenia (5F30AG058381-04). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/9984244. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*